2D'Haens G, Sandbonl WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis [ J ]. Gastroenterology, 2007, 132 (2) :763-786. DOI: 10. 1053/j.gastro.2006. 12. 038.
7Hirai F, Matsui T, Aoyagi K, et al. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices [ J ]. Dig Endosc, 2010,22 ( 1 ) : 39-44. DOI : 10. 111 l/j. 1443- 1661. 2009. 00916.x.
8Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biolog- ical, and histologic parameters as predictors of relapse in ulcera- tive colitis[ J]. Gastroenterology, 2001,120( 1 ) : 13-20.
10Zhang Q, Sha S, Xu B, et al. Prevalence of colorectal cancer in patients with ulcerative colitis: A retrospective, monocentcr study in China[ J ]. J Cancer Res Ther, 2015,11 (4) : 899-903. DOI: 10. 4103/0973-1482. 143345.
